New
For roughly 15 years, Prof. John Harris, MD, Chair of Vitiligo Clinic and Research Center at the University of Massachusetts Medical School has been intensely studying the pathogenesis of vitiligo, and working on potential treatments.
In this 30-min audio interview with Dr. Brad Glick from HCP Live, Prof. Harris provided insight into his decades on research of inflammatory skin disorders. He also offered an in-depth analysis on the most recent data surrounding vitiligo, and promising new therapies involving topical steroids, JAK inhibitors and more.
FAQOther Questions
- Polypodium leucotomos as an adjunct treatment for vitiligo?
The tropical fern Polypodium leucotomos (also known as Polypodium aureum) and its relative Polypodium decumanumhave shown potential benefits for managing vitiligo and other auto...
- Does vitiligo increase the risk of skin cancer?
No, it does not. Despite common misconceptions, people with vitiligo are actually at a lower risk of developing skin cancer—including both nonmelanoma skin cancer (NMSC) and mal...
- Will it spread?
Vitiligo's progression and response to treatment can vary significantly among individuals, making it a particularly unpredictable skin condition. Based on the VALIANT study, her...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.